An endothelin antagonist for resistant hypertension.

摘要

I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues, which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.